Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Astellas Sees Further FDA Action On Prograf MR In Early 2008

This article was originally published in PharmAsia News

Executive Summary

Astellas responded in July to an "approvable" letter received in January for use of the immunosuppressant Prograf MR (tacrolimus) in liver transplantation, the Japanese pharma revealed during its first quarter 2007 earnings call August 1

You may also be interested in...



Schering-Plough Pulls Garenoxacin Application In Europe

Action comes one year after the company withdrew an NDA for the antibiotic in the U.S.

Death Reported In Phase II Trial For Astellas/FibroGen’s Oral EPO Candidate

Announcement comes just ahead of an FDA advisory committee meeting to discuss EPO products.

Astellas’ Prograf “Approvable” For Use In Combination With Roche’s CellCept

Firm will meet with FDA to get combination therapy for prevention of kidney transplant rejection approved.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC066441

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel